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 41 
ABSTRACT 42 
Cancerous Inhibitor of protein phosphatase 2A (CIP2A) is an adverse biomarker 43 
across many malignancies. Using K562 cells engineered to have high or low CIP2A 44 
expression, we show that high CIP2A levels significantly bias cellular energy 45 
production towards oxidative phosphorylation (OXPHOS) rather than glycolysis. 46 
Mass spectrometric analysis of CIP2A interactors and isobaric tagging for relative 47 
and absolute protein quantitation (ITRAQ) experiments identified many associated 48 
proteins, several of which co-vary with CIP2A level. Many of these CIP2A 49 
associating and co-varying proteins are involved in energy metabolism including 50 
OXPHOS, or in 5' AMP-activated protein kinase (AMPK) signalling, and manipulating 51 
AMPK activity mimics the effects of low/high CIP2A on OXPHOS. These effects are 52 
dependent on the availability of nutrients, driven by metabolic changes caused by 53 
CIP2A. CIP2A level did not affect starvation induced AMPK phosphorylation of Unc-54 
51 autophagy activating kinase 1 (ULK-1) at Ser555, but autophagy activity 55 
correlated with an increase of AMPK activity, to suggest that some AMPK processes 56 
are uncoupled by CIP2A, likely via its inhibition of protein phosphatase 2A (PP2A). 57 
The data demonstrate that AMPK mediates this novel CIP2A effect on energy 58 
generation in malignant cells. 59 
 60 
 61 
 62 
SIGNIFICANCE 63 
High levels of CIP2A are associated with poor clinical outcome in at least 20 different 64 
malignancies, making it an attractive therapeutic target. CIP2A inhibits PP2A and 65 
stabilises MYC. We show a novel association between CIP2A and OXPHOS, via 66 
AMPK signalling, suggesting a new therapeutic network to overcome CIP2A-67 
mediated poor prognosis. 68 
 69 
 70 
Keywords: Cancerous inhibitor of protein phosphatase 2A, CIP2A, protein phosphatase 2A, 71 
PP2A, 5' AMP-activated protein kinase, AMPK, leukaemia, cancer, oxidative 72 
phosphorylation, OXPHOS 73 
 74 
 75 
INTRODUCTION 76 
 77 
     Protein phosphatase 2A (PP2A) is an abundant cellular phosphatase. It is central to 78 
reversing substrate phosphorylation caused by the overactive kinase events that 79 
characterise most human malignancies. Many of these inappropriately phosphorylated 80 
substrates contribute to deranged cellular processes that contribute to the malignant 81 
phenotype. PP2A is thus an important tumour suppressor. 82 
     Phosphorylation of PP2A at tyrosine residue 307 (P-Tyr-307-PP2A) leads to PP2A 83 
inactivation. PP2A is suppressed in many human malignancies; indeed malignant 84 
transformation may require suppression of PP2A activity [1]. PP2A suppression in 85 
malignancy is almost entirely due to its natural inhibitors. Of these, cancerous inhibitor of 86 
PP2A (CIP2A) has emerged as an important oncogene since its discovery [2] and the 87 
recognition of its interaction with PP2A by Westermarck and colleagues [3]. To date, over 88 
220 papers have been published on the clinical consequences of high CIP2A levels in 89 
malignancies, and all associate higher levels with a poor outcome, adverse histology and/or 90 
a poor response to treatment (meta-analysis by Tang et al 2018 [4]), in both common and 91 
rarer epithelial tumour types, and in chronic [5,6] and acute [7] myeloid leukaemias. 92 
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     In contrast to this breadth of clinical correlative information, little is known of CIP2A’s 93 
mechanism of action. A direct interaction between CIP2A and PP2A has been described, 94 
showing CIP2A binds at least two PP2A regulatory subunits, specifically β56γ and β56α [8]. 95 
The structure of the N-terminal region (residues 1-560) of CIP2A has been determined. This 96 
region is important in facilitating PP2A binding, as it contains the homodimer contacts, 97 
spanning residues 507-559 that enhance CIP2A’s binding to PP2A subunits. The minimum 98 
region required for CIP2A binding to β56α and β56γ has been identified as residues 159-245 99 
[8]; however a structure containing both CIP2A and PP2A components has yet to be 100 
identified. Whether these interactions fulfil all CIP2A binding are unknown as despite efforts 101 
by us and others, the full length protein is unstable and has not yielded any crystals for X-ray 102 
crystallographic structural study.   103 
     In CIP2A immunoprecipitation experiments from Hela cells, CIP2A associates with MYC 104 
[3]. This interaction is direct and involves the N-terminal residues 1-262 of MYC.  CIP2A 105 
level enhances MYC expression and activation (indicated by phosphorylation on serine 62 106 
(P-Ser-62-MYC)) and MYC localisation to nuclear lamins in cancer cell lines [9-11]. The 107 
mechanism for CIP2A’s regulation on MYC is likely through its inhibitory effect on PP2A-108 
mediated MYC dephosphorylation (which inactivates MYC and decreases its stability). 109 
However, the possibility that CIP2A may also have additional actions has not been 110 
examined.     Using the chronic myeloid leukaemia (CML) cell line K562 engineered to have 111 
either high or low levels of CIP2A, we here present evidence that CIP2A augments oxidative 112 
phosphorylation (OXPHOS) and decreases reliance on glycolysis. Also, CIP2A directly 113 
interacts with a number of proteins that are involved in energy metabolism in a manner 114 
suggesting that these metabolic effects are mediated through 5' adenosine monophosphate-115 
activated protein kinase (AMPK), and this is supported by the observation that modifying 116 
AMPK activity mimics the effects of CIP2A on energy metabolism. These findings constitute 117 
a novel mechanism of action for CIP2A in malignancy. 118 
 119 
 120 
MATERIALS AND METHODS 121 
 122 
K562 fractionation and western blots 123 
     K562 lysates were prepared in RIPA buffer containing halt™ protease inhibitor 124 
(ThermoFisher Scientific, Loughborough, Leicestershire, UK) and 2mM phosphatase 125 
inhibitor (2mM NaVO4 Sigma-Aldrich, Gillingham, Dorset, UK). Cell lysis was achieved by 126 
sonication and the supernatant was collected after removing cell debris by centrifugation at 127 
16,000g at 4°C. Supernatants were quantified by DC™ protein determination kit (Bio-Rad, 128 
Watford, Hertfordshire, UK) and loaded at 20μg per well for western blot analysis. CIP2A 129 
components were probed using antibodies for CIP2A (Santa Cruz, Dallas, Texas, US), PP2A 130 
C (Millipore, Watford, Hertfordshire, UK), PP2A C (recognising P-Tyr-307-PP2A) (Santa 131 
Cruz), MYC (Santa Cruz) and P-Ser-62-MYC (Abcam, Milton, Cambridgeshire, UK). 132 
Kaleidoscope™ molecular weight markers (Bio-Rad) were used to estimate molecular 133 
masses, and shown relative to the target of interest in kDa as indicated. Nuclear and 134 
cytoplasmic fractionation was achieved as described in the NE-PER Nuclear and 135 
Cytoplasmic reagent kit protocol (ThermoFisher Scientific). The control and secondary 136 
antibodies used were Poly (ADP-ribose) polymerase (PARP, Abcam), β-actin (Sigma-137 
Aldrich) and conjugate horseradish peroxidase containing antibodies raised against mouse 138 
or rabbit (Cell Signalling Technologies, Danvers, Massachusetts, U.S.) respectively. The 139 
AMPK and P-Thr-172 AMPK antibodies used for assessing the AMPK signalling 140 
components and glucose transporter type 4 (GLUT4) were all from Cell Signalling 141 
Technologies. To quantitate autophagy, antibodies from Cell Signalling Technologies were 142 
used to assess relative levels of the AMPK target, Unc-51 like autophagy activating kinase 1 143 
(ULK-1), phosphorylated at Ser 555 and the autophagy marker, microtubule-associated 144 
protein 1A/1B light chain 3, isoform B,  recognising both cytosolic (LC3I) and 145 
autophagosome associated form (LC3II). Drug treatments 5-aminoimidazole-4-carboxamide 146 
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ribonucleotide (AICAR) (Abcam), A-769662 (Abcam), Compound C (Abcam) and okadaic 147 
acid (Cayman Chemical Company, Ann Arbor, Michigan, U.S.) were included at the final 148 
concentrations and incubation times stated, at 5x105/ml cell density. 149 
   150 
 151 
Low and high fed conditions 152 
     To generate low and high nutrient conditions, the CIP2A modified cell lines were fed at a 153 
cell density of 1x106 cells/ml in RPMI with phenol red pH indicator included (Sigma-Aldrich), 154 
supplemented with 2mM L-glutamine (ThermoFisher Scientific) and 100 U/0.1mg/ml 155 
penicillin streptomycin (ThermoFisher Scientific) and left for 3 days at 37°C in a CO2 156 
incubator. The colour of the media changed to yellow, indicating a reduction in pH by the 157 
phenol indicator. Lysates were then collected for starved cells as previously described. For 158 
fed conditions, starved cells were fed in the fresh media at a cell density of 1x106 cells/ml 159 
and left for 24 hours as similarly described with no noticeable change to the colouration of 160 
the media.   161 
 162 
 163 
Generation of CIP2A modified cell lines and Lentiviral Vector Design 164 
     The CIP2A (accession number: NM_020890) coding sequence was amplified from a 165 
CIP2A plasmid (NM_020890) human tagged ORF clone (Origene, Wembley, Middlesex, UK) 166 
and K562 DNA respectively, with necessary recombination sequences and transferred into a 167 
pLNT transfer vector for CIP2A+ and CIP2A- respectively using standard Gateway calking 168 
protocols. CIP2A destination vectors were then separately cloned into a venus C-fusion 169 
lentiviral vector (pLNT-UbC-#-venus) for either CIP2A+, generously donated by Prof. Mike 170 
White at the University of Manchester, UK or in psPAX2 for the generation of CIP2A-. The 171 
propagation and cloning of the lentiviral vectors and lentivirus production using HEK293T 172 
cells and subsequent transfection of K562 cells were performed as described for CIP2A+ 173 
[12] and for CIP2A- [13]. The cell lines generated were derived from a single transfection. 174 
 175 
 176 
Flow cytometry and determination of cellular size, proliferation and survival. 177 
     Cellular sizes, proliferation and annexin V/propidium iodide (PI) survival assays were all 178 
performed on the Attune NxT flow cytometer (ThermoFisher Scientific). Flow speeds were 179 
set at 100ul/min and voltage settings were consistent between all cell lines in each 180 
respective experiment.  181 
     Changes in cell size between CIP2A modified cell lines were assessed by comparing 182 
differences between side and forward scatter profiles of the main cell population. The 183 
geometric mean for the forward scatter and count was taken and overlaid as histograms, 184 
constructed using Flojo™ version 10 software (BD, Ashland, Oregon, US). Proliferation was 185 
assessed by comparing the fluorescent decline of carboxyfluorescein succinimidyl ester 186 
(CFSE), caused by dividing cells and dilution of the signal over 0h, 14h, 24h, 48h, 72h and 187 
84h timepoints. Briefly, cells were washed in PBS, treated with Far-red CFSE (ThermoFisher 188 
Scientific) at a final concentration of 0.5μM and incubated at 37°C for 30 minutes, protected 189 
from light and shaken every 5 minutes throughout this period. CFSE was removed by 190 
centrifugating cells at 500g and removing media. Cell pellets were washed in RPMI, rested 191 
for 15 minutes in a CO2 incubator set at 37°C and similarly washed twice more in complete 192 
RPMI media. Untreated and CFSE treated cell populations were then measured by flow 193 
cytometry, using red-laser1 (RL1) at the times specified.  194 
     Cell survival was tested in both high and low nutrient conditions. Annexin V binding buffer 195 
(10mM HEPES, 150Mm NaCl and 2.5mM CaCl2, made in PBS at pH 7.4) including 5% of 196 
Alexa fluor 647 annexin V (Biolegends, San Diego, California, US) was added to achieve a 197 
50% mix. Immediately before flow cytometry assessment, 2μl of a 1:20 dilution of PI (Sigma-198 
Aldrich) was added to the mix, shaken and the blue laser3 and RL1 were used to detect the 199 
fluorescence emitted from PI and Alexa fluor 647 annexin V respectively. Viable, early and 200 
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late apoptotic populations (annexin V -/PI-, annexin V+/PI- and annexin V +/PI+ respectively) 201 
were assessed using the Attune NxT software (ThermoFisher Scientific). 202 
     Experiments were repeated 3 times for each cell line in all flow cytometry experiments. 203 
Statistical analysis was carried out using Graphpad Prism version 7 (GraphPad, La Jolla, 204 
California, US) and unpaired Student’s T-test. 205 
 206 
 207 
Seahorse Metabolic Assays 208 
     All seahorse consumables were purchased from Agilent (Agilent, Cheadle, Greater 209 
Manchester, UK). XF96 cell culture microplates (Agilent) were pre-treated with 10μl of 210 
22μg/ml cell-tak™ solution (ThermoFisher Scientific), in 0.1M bicarbonate buffer at pH 8 the 211 
previous day, as described in the manufacturers’ protocol. Each K562 cell line was washed 212 
and suspended in unbuffered Seahorse XF base media (Agilent), containing 1mM sodium 213 
pyruvate and 2mM L-glutamine at pH 7.4. D-glucose at 25mM was added for mitochondrial 214 
stress testing. A total of 70,000 cells from each K562 cell line were added per well, and 215 
attached by centrifugation at 50g over 5 minutes, with minimum accelerating and 216 
decelerating speeds set, then settled at 37°C in a CO2-free incubator for at least 30 minutes 217 
prior to seahorse analysis.  218 
     The XF injection plate for the mitochondrial stress test was set up to dispense 25μl for 219 
final concentrations of 1.5μM oligomycin A, 0.75μM carbonyl cyanide-4-220 
(trifluoromethoxy)phenylhydrazone (FCCP) and 1μM each of rotenone and antimycin A. For 221 
the glycolysis stress test, 10mM D-glucose, 1.5μM oligomycin A and 100μM 2-deoxy-D-222 
glucose were used. Experiments were run over 75 minutes using Seahorse XF96 223 
instrumentation (Agilent). Three replicates for each stress test were performed, with each 224 
containing at least 3 technical replicates to construct an averaged profile for each of the 3 225 
K562 cell lines. Data were analysed using Wave 2.4 (Agilent) and normalised to non-226 
glycolytic acidification at the final point before the addition of glucose or to non-mitochondrial 227 
respiration respectively. Mitochondrial stress tests adapted to incorporate AMPK modifying 228 
compounds, 4mM AICAR (Abcam) and 10μM Compound C (Abcam) were run as described 229 
with an extra stage measuring each compound’s effect after initial basal measurement over 230 
the course of an hour, compared against initial basal rate or relative vehicle control as 231 
specified. Column plots were constructed using with standard error using Graphpad Prism 232 
Version 7 (GraphPad, La Jolla, California, US) and unpaired Student’s T-test with Welch 233 
correction was used for statistical analysis. 234 
 235 
Protein Extraction and ITRAQ labelling 236 
     A total of 1x108 cells from each K562 derived cell line were twice washed in PBS then 237 
resuspended and lysed in 0.5M triethylammonium bicarbonate (TEAB) (Sigma-Aldrich) and 238 
1% sodium dodecyl sulphate (SDS) (Sigma-Aldrich) at 4°C. Concentrated Halt™ protease 239 
and phosphatase inhibitors were then added to achieve the recommended 1x working 240 
concentration (ThermoFisher Scientific). Prior to isobaric tagging for relative and absolute 241 
protein quantitation (ITRAQ), samples were diluted 10-fold in 0.5M TEAB, to reduce 242 
protease inhibitor concentration and allow for overnight trypsin digestion. The final protein 243 
concentrations were made to 100μg protein in 20μl volume, as determined by Bradford 244 
assay [14] (ThermoFisher Scientific). Labelling for the 8plex ITRAQ methodology was 245 
according to the SCIEX protocol as used previously [15]. Briefly, protein lysates were 246 
reduced in 1mM tris(2-carboxyethyl)phosphine (TCEP) (ThermoFisher Scientific), and self-247 
linking cysteine residues capped by treatment with 10mM methyl methanethiosulfate 248 
(MMTS) agent (ThermoFisher Scientific) before overnight trypsin digestion, using trypsin 249 
gold™ graded for MS use (Promega, Madison, Wisconsin, US). The trypsinised protein 250 
samples were then labelled with 8plex ITRAQ tagging reagents, using all available mass 251 
labels, ranging from 113-121 (SCIEX, Framingham, Massachusetts, US). Samples were 252 
brought to pH 3 with phosphoric acid and the complex protein mixture was cleaned and 253 
fractionated by strong-cation exchange chromatography (Polysulfoethyl A column 200 x 254 
4.6mm, 5μm, 300Å; Poly LC, Columbia, Maryland, US). 2ml fractions containing protein 255 
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were dried under vacuum (SpeedVac, Eppendorf, Stevenage, UK) and reconstituted in 1ml 256 
0.1% trifluoroacetic acid (Sigma-Aldrich) before desalting on a mRP Hi Recovery column 257 
(4.6 x 50mm, Agilent) using an Agilent 1260 HPLC system (Agilent). 258 
 259 
Mass spectrometry setup and parameters 260 
     Desalted fractions were reconstituted into 40μl of 0.1% formic acid (Sigma-Aldrich) and 261 
delivered into a TripleTOF 6600 system (SCIEX) in 5μl aliquots via an Eksigent NanoLC 400 262 
system (SCIEX) mounted with a NanoAcquity (5μm, 180μm x 20mm) C18 trap and analytical 263 
column (1.7μm, 75μm x 250mm, Waters, Wilmslow, Cheshire, UK). A NanoSpray III source 264 
was fitted with a 10μm inner-diameter PicoTip emitter (New Objective, Woburn, 265 
Massachusetts, US). A gradient from 2-50% acetonitrile/ 0.1% formic acid was applied over 266 
90 minutes at 0.3μl/min. Peptide spectra were acquired in positive ion mode using 267 
information-dependent acquisition by the Analyst TF1.7 software (SCIEX), with survey scans 268 
of 250ms. The MS/MS accumulation time was set for 100ms with monitoring of the 25 most 269 
intense ions (total cycle time 2.75s). 270 
 271 
Mass spectrometry data processing 272 
     Data were searched using ProteinPilot5 software (SCIEX) against the UniProt database 273 
(release-2017_03, 20 201 human proteins), set to incorporate ITRAQ and MMTS as 274 
modifications. Data were also searched against a reverse database, to eliminate proteins 275 
that lay outside the 1% false discovery rate limit. A total of 6 biological repeats were obtained 276 
from merging four ITRAQ experiments. The experiments were performed as two sets of two 277 
8plex experiments with a reference pool shared between pairs.  The merged data were 278 
reduced to contain proteins identified by at least 1 peptide at 99% confidence or 2 peptides 279 
at 90%. These data were Log2 transformed and processed using the batch-correction 280 
feature of Partek genomic suite 7 (Partek Genomic Suite software, v. 7.18.0518, St. Louis, 281 
Missouri, US) to eliminate pool and ITRAQ experiment biases. Protein changes between cell 282 
lines were tested using these data and an ANOVA analysis was utilised to identify 283 
differences between cell types.  As a precaution, the data prior to batch correction were also 284 
tested using an ANOVA with these factors included as variables, and proteins not present in 285 
both sets of analysis were removed. Principal component analysis (PCA) was performed 286 
using Partek genomic suite on these batch-corrected data. The heatmap showing significant 287 
changes (p<0.05) by ANOVA between CIP2A+ and CIP2A- was Zscored with incomplete 288 
datasets removed prior to analysis by Perseus Proteomic Software suite (Max Planck 289 
Institute, Munich, Germany) [16]. The heatmap was constructed using Euclidean linkages to 290 
sort both row and column values with default settings applied. Pathway analyses were 291 
performed using DAVIDdb [17,18].  292 
 293 
Immunoprecipitations and CIP2A-venus extraction 294 
     CIP2A was isolated using immunoprecipitations (IP) on protein lysates from K562 cells.  295 
A venus fluorophore tagged version of CIP2A was also immunoprecipitated from CIP2A+ 296 
cell line protein lysates. Each isolation experiment used 1x108 cells for each respective cell 297 
line. Protein lysates were prepared by sonication in 50mM Tris-HCL pH 8, 150mM NaCl, 298 
1mM EDTA, 1mM EGTA and 0.1% Triton X100 including Halt™ protease and phosphatase 299 
inhibitors (ThermoFisher Scientific). Prior to IP, protein A/G magnetic beads (ThermoFisher 300 
Scientific) were precoated with the target’s respective antibody using 20μg/50μg of bead.  301 
For CIP2A IP, two antibodies were used targeting either its N’ or C’-terminal (ab128179; 302 
Abcam, & sc80660; Santa Cruz respectively) alongside a mouse control (ab18447, Abcam) 303 
performed identically. The CIP2A-venus targeted pull-down was incubated for two hours on 304 
ice and washed twice in the same buffer and extracted using 20μl GFPtrap™ beads 305 
(ChromoTek, Planegg-Martinsried, Germany). 306 
     Prior to mass spectrometry analysis, samples were washed twice more in phosphate 307 
buffer (PB) at pH 7.4, pelleted and resuspended in 100μl PB with 10mM dithiothreitol (DTT) 308 
(Sigma-Aldrich) and incubated at room temperature for 15 min. The cysteine capping 309 
reagent iodoacetamide (Sigma-Aldrich) was added to stop the reforming of disulphide 310 
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bonds, at 50mM final concentration and incubated at 15 min at room temperature. This was 311 
then washed three times in 100μL PB and resuspended in 50μl with 0.5μg trypsin (Promega) 312 
and incubated overnight at 37°C. Samples were cleaned from contaminants using C18 313 
ZipTips (Millipore). A total of 2 ZipTips were used to pool 20μl from each sample. 5μl of the 314 
zip-tipped sample was analysed on a Triple TOF 6600 as described above. The resulting 315 
protein lists were further subtracted, using results obtained from an antibody control of same 316 
species or GFPtrap™ control (using only unmodified K562 lysate); both were run parallel to 317 
the IP test experiments. Data were analysed using DAVID and cytoscape with STRING app; 318 
pValues were obtained from STRING EASE scoring. Protein associations and interactions 319 
were identified and visualised using Cytoscape [19,20] and installed apps STRING [21].  320 
 321 
 322 
RESULTS 323 
 324 
Verification of CIP2A level in modified cell lines 325 
     To investigate the effects of CIP2A, 2 lentiviral-modified K562 cell lines were generated. 326 
These either overexpressed venus fluorophore tagged CIP2A (CIP2A+) or had CIP2A 327 
expression knocked down via shRNA (CIP2A-). The CIP2A level of each line together with 328 
unmodified K562 cells was validated by western blot, shown in Figure 1A, which 329 
demonstrates a knock-down efficiency of over 98% in the CIP2A- line and an extra band 330 
corresponding to the expected molecular weight of the CIP2A-venus tagged construct in the 331 
CIP2A+ cell line. A correlation was observed between the CIP2A level and active MYC (P-332 
Ser-62-MYC), along with an increase in inactive PP2A (P-Tyr-307-PP2A, Figure 1A), 333 
confirming that CIP2A is in an active conformation in these cells and consistent with other 334 
reports [3,5]. CIP2A was predominantly located in the cytoplasm together with PP2A, 335 
whereas MYC was mostly expressed in the nuclear compartment and this was similar for all 336 
cell lines (Figure 1B), suggesting that CIP2A activity resides within the cytoplasm and 337 
consistent with findings in other cancers [22,23]. 338 
     Figure 1C demonstrates that there was no difference in cell size, assessed cytometrically 339 
by forward and side light scatter, between unmodified and CIP2A+ or CIP2A- cell lines; 340 
furthermore this was consistent in both high and low nutrient conditions. Similarly, Figure 1D 341 
shows no difference between the lines in cell viability and apoptosis rate, with each cell line 342 
in low nutrient conditions remaining at least 85% viable and less than 5% and 6% 343 
undergoing early and late apoptosis respectively. Proliferation rates were also assessed by 344 
the decay rate of a CFSE signal due to cell division, and again no differences between the 345 
cell lines were observed (all comparisons p>0.3, Student’s T-test (data not shown). 346 
Modifying the CIP2A level therefore does not alter cell size, viability or proliferation rates. 347 
 348 
 349 
CIP2A increases mitochondrial respiration without compromising glycolytic processes 350 
     To explore the impact of CIP2A on energy metabolism, seahorse energy metabolic stress 351 
assays were carried out using these CIP2A modified K562 cells, together with unmodified 352 
cells. Glycolysis was assessed by the extracellular acidification rate (ECAR) mainly resulting 353 
from lactate production, and mitochondrial OXPHOS by the oxygen consumption rate (OCR) 354 
driven by the components of the electron transport chain. A variety of compounds were used 355 
to manipulate these processes, as shown schematically in Figure 2A and 2E and described 356 
in their legend. 357 
     Figure 2A-2D show that reliance on glycolysis differs according to CIP2A level. The basal 358 
rate of glycolysis, in the presence of glucose, was significantly lower in CIP2A+ cells than in 359 
either CIP2A- or unmodified cells (p < 0.0001; Figure 2A and 2B). However, CIP2A did not 360 
impair the glycolytic machinery, since forcing cellular energy production to rely solely on 361 
glycolysis (by inhibiting mitochondrial respiration by OXPHOS with oligomycin A, an 362 
adenosine triphosphate (ATP) synthase inhibitor) allowed all cells to reach a comparable 363 
maximum rate of glycolysis (Figure 2C). A higher CIP2A level correlated with an increased 364 
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spare glycolytic capacity (p < 0.05; Figure 2D), thus demonstrating that CIP2A does not 365 
permanently disrupt any of the key glycolytic components and suggesting that mitochondrial 366 
activity may be higher in the CIP2A+ cell line.  367 
 The effect of CIP2A level on mitochondrial metabolism was tested in the same 368 
system, by measuring the OCR and its response to OXPHOS manipulating compounds. A 369 
higher CIP2A level correlated with an increased basal rate of OXPHOS (p < 0.05; Figure 2E 370 
and 2F). This increase in OXPHOS was reliant on the components of the electron transport 371 
chain, as when ATP synthase was blocked by oligomycin A, the OCR fell to a similar level 372 
irrespective of CIP2A status (Figure 2E). ATP synthase-driven ATP production was therefore 373 
more active in the high CIP2A phenotypes (p < 0.05; Figure 2G). The maximum rate of 374 
OXPHOS was determined by treatment with FCCP, an electron transport chain uncoupling 375 
agent; this demonstrated that the CIP2A level is significantly correlated to the maximum rate 376 
and spare capacity of OXPHOS (p < 0.05; Figure 2H and 2I).      377 
 378 
 379 
CIP2A alters expression of proteins involved in energy metabolic processes, including AMPK 380 
signalling 381 
     To understand how CIP2A increases OXPHOS, differences in the proteome between 382 
each cell line were determined. The proteins from the lysate of each CIP2A-modified cell line 383 
were subjected to ITRAQ and were identified and quantified by mass spectrometry.  384 
     A total of 6 biological repeats for each cell line was performed as described over 4 8plex 385 
ITRAQ experiments. Protein levels were expressed as ratios to the reference control in each 386 
run and corrected using batch correction algorithms (Partek Genomic Suite software, v. 387 
7.18.0518, Partek Inc. St. Louis, MO, USA) to improve comparisons between multiple runs, 388 
as similarly described [15]. A total of 229 proteins were expressed at significantly different 389 
levels between the CIP2A+ and CIP2A- cells (defined as p < 0.05 in ANOVA) as shown in 390 
the heat map in Figure 3A and Supplementary Table 1. These data were categorised into 391 
two datasets representing proteins over- and under-expressed with higher CIP2A, and were 392 
individually analysed for pathway enrichment in energy metabolic processes using the 393 
Database for Annotation, Visualisation and Integrated Discovery (DAVID) proteomic suite 394 
[17] and significant Fishers exact test scores (FE), (p<0.05). Of the 229 proteins, 27 were 395 
significantly enriched in energy metabolic pathways identified from the current Kyoto 396 
Encyclopaedia of Genes and Genomes (KEGG) database [24] (Figure 3B and C). Proteins 397 
that were upregulated with higher CIP2A levels were involved in pyruvate metabolism (FE p 398 
= 0.0043) and OXPHOS (FE p = 0.024), contributing to 3 of the 5 functional electron 399 
transport chain components (Figure 3C). This increase is consistent with the mitochondrial 400 
stress test observations of Figure 2E-2I. Similarly, the proteins downregulated with 401 
increasing CIP2A were also associated with several energy metabolic processes, including 402 
AMPK signalling (FE p = 0.0052).  403 
    404 
 405 
CIP2A co-associates with proteins involved in AMPK signalling, glucose uptake and protein 406 
synthesis. 407 
     To further validate the observations from the ITRAQ proteomic analysis, proteins 408 
associating with CIP2A were identified by two techniques: by immunoprecipitation (IP) with 409 
antibodies targeting the N’ or C’ termini of endogenous CIP2A and by GFPtrap beads 410 
targeting the C’ terminal venus fluorophore tag in the CIP2A+ cell line. For each technique, 411 
the CIP2A-associated proteins were then identified by mass spectrometry. 412 
     Results from the GFPtrap experiments identified 587 CIP2A-associated proteins, 413 
compared to 151 and 210 from the N’ and C’ termini targeted IPs respectively (after 414 
subtracting a non-specific antibody control), but only 52 were common to all three IPs 415 
(Figure 4A). These 52 proteins and associated interactions were visualised by the functional 416 
protein association network STRING [21] and annotated according to its databases (Figure 417 
4B). A large proportion of these proteins shared interactions and several fell into one of 3 418 
functional pathways as annotated in the KEGG database [24] using a modified Fischer exact 419 
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(EASE) score (p<0.05) in DAVID (Figure 4B). These were firstly components of the 420 
ribosome complex, involving the small 40S (RPS5, RPS27 and RPS27L) and large 60S 421 
(RPL9, RPL10 and RPL10A) subunits (EASE, p = 0.00084), and secondly spliceosome 422 
assembly complexes (HNRNPU, DDX39B, EIF4A3, SNRPD3, DHX15, PRPF40A) (EASE, p 423 
= 0.00074). 424 
     The third KEGG pathway was AMPK signalling (EASE, p = 0.0043), as also identified in 425 
the ITRAQ experiments. Proteins identified in this pathway included 3 members of the Rab 426 
family of G-proteins (RAB8A, RAB10 and RAB14) which are all relevant to AMPK-directed 427 
translocation of GLUT4, the activity of the platelet isoform of the key glycolytic protein, 428 
phosphofructokinase-1 (PFKP) and eukaryotic elongation factor 2 (EEF2; involved in peptide 429 
elongation during protein synthesis). 430 
 431 
 432 
The effect of CIP2A on AMPK activity is dependent on nutrient availability   433 
     AMPK activation is demonstrated by its phosphorylation on Thr172 (P-Thr-172 AMPK), 434 
and is responsible for the majority of AMPK kinase activity [25]. P-Thr-172 AMPK activation 435 
was found to vary according to whether the availability of nutrients in the media were high 436 
(fed within the previous 24 hours after starvation) or low (fed 72 hours previously). In CIP2A- 437 
cells in low nutrient conditions, AMPK activity is higher than in high nutrient conditions, in line 438 
with the increase in the AMPK substrate GLUT4, which is normally increased by AMPK in 439 
low nutrient availability [26]. However, Figure 5A also shows that unmodified cells (which 440 
have endogenous CIP2A levels close to CIP2A+ cells as shown in Figure 1A) and CIP2A+ 441 
cells are similar in that AMPK activity is high in the high nutrient state (and higher than that in 442 
the corresponding cells in low nutrient conditions). This shows that CIP2A can disrupt normal 443 
AMPK activation conferred by low nutrient availability, whereby cells with high CIP2A have 444 
higher AMPK activity when nutrients are abundant. Furthermore, GLUT4 levels are 445 
significantly increased in both CIP2A overexpressing cells when nutrient levels are high 446 
(Figure 5A, Student’s T-test p<0.03). 447 
     To determine whether an AMPK function other than energy metabolism also co-varied 448 
with CIP2A, phosphorylation of ULK-1 at serine 555 (P-Ser-555-ULK-1) was examined. This 449 
phosphorylation is an early step in autophagy [27, 28]. Figure 5B shows that this is only 450 
elevated in low nutrient conditions, consistent with the activation of AMPK in such conditions 451 
as seen when directly measured by P-Thr-172-AMPK in Figure 5A. However, unlike direct 452 
measurement of AMPK activity, no difference in ULK-1 levels is seen between CIP2A- and 453 
unmodified/CIP2A+ cells (Figure 5B). Autophagy was also investigated by levels of the 454 
cytosolic form of microtubule-associated protein 1A/1B-light chain 3 (LC3I) and a version of 455 
LC3I conjugated to phosphatidylethanolamine (LC3II, associated with starvation-induced 456 
autophagic activity [29]. LC3I and LC3II levels were highest in low nutrient conditions in all 457 
cell lines, consistent with higher AMPK activity in such conditions. Interestingly, Figure 5B 458 
also shows that the ratio of LC3II to LC3I, an index of autophagy [30] is significantly higher in 459 
unmodified or CIP2A+ cells than in CIP2A- cells in fed (post 24h) conditions (p=0.05 and 460 
0.0224 respectively). These findings are therefore analogous to the findings of AMPK activity 461 
when measured directly by P-Thr-172-AMPK.   462 
      463 
 464 
The effect of CIP2A on OXPHOS is mediated by AMPK activity via PP2A and independent 465 
of MYC activity.  466 
 To further investigate the effect of AMPK on metabolism, AICAR, an AMPK activator, 467 
was added to CIP2A- cells in high nutrient conditions (where AMPK activity is low as shown 468 
in Figure 5A). This significantly increased the basal rate of OXPHOS by 35% (19 pmol/min 469 
above basal, p = 0.0368, Student’s T-test), without effect on the maximum capacity of 470 
OXPHOS (Figure 6A and 6B). Similar effects were seen with the alternative AMPK activator 471 
A-769662 at a concentration of 3 uM and 1 hour incubation (data not shown). In the 472 
converse experiment, the AMPK inhibitor Compound C was added to CIP2A+ cells in high 473 
nutrient conditions, where AMPK activity is high (as shown in Figure 5A). This significantly 474 
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reduced both basal levels and maximum rate of OXPHOS by 20% (20 pmol/min difference, p 475 
= 0.0012) and reduced the maximum capacity by half (97 pmol/min difference when 476 
normalised to each respective basal rate p < 0.001) respectively (Figure 6C and 6D). Figure 477 
6A and 6C respectively show that AICAR and Compound C alter the phosphorylation status 478 
of AMPK as expected [31,32]. AMPK activity therefore affects OXPHOS, and may be an 479 
important mediator in the effect of CIP2A on energy metabolism in malignant cells. 480 
     In order to determine whether CIP2A regulation of AMPK is mediated through its known 481 
regulation on PP2A, PP2A was inhibited by addition of the phosphatase inhibitor okadaic 482 
acid in CIP2A- cells. As expected, okadaic acid decreased PP2A activity (as shown by an 483 
increased level of P-Tyr-307-PP2A) in a concentration dependent manner (Figure 5C). The 484 
inactivity of PP2A correlated with increased AMPK activity (as assessed by P-Thr-172 485 
AMPK, showing that inhibition of PP2A by okadaic acid could mimic the changes in AMPK 486 
activity observed in the CIP2A+ cells (Figure 5A). Activation of AMPK by AICAR also had 487 
little effect on activity of P-Ser-62-MYC levels (data not shown), suggesting that MYC 488 
activity does not play a significant role in CIP2A’s regulation of AMPK.    489 
 490 
  491 
 492 
DISCUSSION 493 
 494 
     CIP2A has emerged as an important indicator of adverse outcome in cancer in the past 495 
decade, and its value as a clinically useful biomarker for individual tumour types is under 496 
investigation. At the molecular level, its interactions with PP2A and MYC have been 497 
described [3,8], but little is known of other interactions. Here we extend knowledge of the 498 
biology of CIP2A by carrying out seahorse metabolic stress assays in neoplastic cells 499 
engineered to have high or low CIP2A levels, and by mass spectrometry on ITRAQ studies 500 
and CIP2A pulldowns (both IP and tagged) in these cells. Three principal findings emerge 501 
from these studies. First, the seahorse stress assays show an increase in basal OXPHOS 502 
and a decrease in glycolysis in CIP2A+ cells. Second, proteins involved in several energy 503 
metabolic processes co-vary with CIP2A expression as revealed by ITRAQ and include 504 
those involved in not only OXPHOS but also the signalling of AMPK, an established key 505 
energy metabolism mediator. And third, manipulation of AMPK activity may modify the 506 
metabolic effects of CIP2A, through known inhibition of PP2A. 507 
     OXPHOS is a crucial cellular process, producing most of the cell’s energy in the form of 508 
ATP. The observation that OXPHOS (respiration) is suppressed in malignant cells and may 509 
be accompanied by a compensatory increase in glycolysis, was made almost a century ago, 510 
and was later termed the Warburg effect after the pioneer of much of this initial work 511 
(reviewed by Liberti and Locasale [33]). Warburg proposed that this is due to dysfunctional 512 
mitochondria, and subsequent suggestions for mechanism have included imbalances in 513 
intracellular pH, defects in ATPase activity, and aberrant growth factor signalling. The 514 
increased production of lactate that results from increased glycolysis may lead to local 515 
acidosis around tumours and this may enhance tumour invasiveness [34]. However, the 516 
mechanism of the Warburg effect remains uncertain, nor is it clear whether it is a 517 
consequence of other tumour-related lesions. Here we demonstrate in a malignant cell line a 518 
phenomenon opposite to the Warburg effect, namely that high levels of CIP2A will augment 519 
OXPHOS. CIP2A has recently been reported to both suppress glycolysis in primary cilia [35], 520 
and enhance it in non-small lung cancer [36], but to the best of our knowledge it has not 521 
been reported to enhance respiration in malignancy. In fact, the Warburg effect is not 522 
universal in malignant cells; indeed early work also established that respiration is variable in 523 
tumours, and may be substantial [37], compatible with the possibility that other factors may 524 
mitigate a general Warburg effect across malignancy. 525 
    AMPK is a heterotrimeric protein, consisting of two regulatory subunits (β and γ) and a 526 
catalytic subunit; 80% of its activity is due to the α1 isoform (PRKAA1) and γ1 regulatory 527 
subunit (PRKAG1) [38].  AMPK is a master sensor of energy status [39] and becomes 528 
activated once glucose or oxygen become limited or the ADP/AMP to ATP ratio becomes 529 
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high. A key function of active AMPK is in increasing ATP-producing catabolic processes 530 
such as glucose uptake, glycolysis and OXPHOS, whilst reducing ATP usage in anabolic 531 
processes. When activated, AMPK promotes glycolysis (via activation of 532 
phosphofructokinase-2 (PFK-2) and formation of fructose-2,6-biphosphate, a potent activator 533 
of phosphofructokinase-1 (PFK-1) which is rate limiting in glycolysis [40]. Active AMPK also 534 
promotes the biosynthesis of new [41] and the disposal of dysfunctional mitochondria [42] 535 
and has been shown to induce OXPHOS function in T cell acute lymphoblastic leukaemia 536 
and electron transport chain complex I activity [43]. 537 
     The present ITRAQ data show that high CIP2A is associated with lower levels of the two 538 
key AMPK components PRKAA1 and PRKAG1, and seahorse and proteomic analysis data 539 
show this is associated with reduced glycolysis. This reduced AMPK activity is also 540 
associated with a decrease in PFK-platelet type (PFKP, a component of the PFK-1 complex) 541 
to reduce glycolysis. Furthermore, high levels of CIP2A are associated with enhanced 542 
OXPHOS and an increased expression of electron transport chain components. In high 543 
CIP2A cells, two PP2A subunits were also decreased (see supplementary Table S1); the β 544 
isoform of the scaffold subunit, PPP2R1B and the α form of the β56 regulatory subunit, 545 
PPP2R5A (β56α), consistent with a reduction of PP2A activity. PP2A complexes containing 546 
the regulatory β55δ or β56γ subunits are known to directly dephosphorylate and inactivate 547 
AMPK [44-46]. In support of this, the inhibition of PP2A by okadaic acid may mimic the effect 548 
of high CIP2A, providing a potential mechanism driven by the CIP2A-PP2A interaction and 549 
regulation of AMPK activity. Nutrient availability is also a key regulator of this process, in 550 
conjunction with other studies, where CIP2A-mediated regulation of the cAMP responsive 551 
element binding protein (CREB) activity (an AMPK substrate [47,48] ) was also dependent 552 
on high levels of both nutrients and CIP2A in the non-small cell lung cancer cell line H1299 553 
[36]. Here we show that AMPK activity as measured by P-Thr-172-AMPK is elevated not 554 
only in low nutrient conditions but also in high nutrient conditions where CIP2A is also high. 555 
High CIP2A levels also modify the level of autophagy in a similar pattern when assessed by 556 
LC3II/LC3I ratio though not when assessed by serine 555 phosphorylation of ULK-1, 557 
suggesting that factors that normally mediate AMPK activity are uncoupled by CIP2A. There 558 
is evidence that AMPK can be uncoupled from autophagy events [49]. AMPK activity may 559 
also be mediated by levels of metabolites derived from metabolic pathways independent of 560 
glucose metabolism. In starved C2C12 mouse muscle cells lacking glucose and amino 561 
acids, reintroduction of free amino acids enhances the expression of P-Thr-172-AMPK, 562 
suggesting AMPK activity can be increased independently of glucose availability [50]. CIP2A 563 
has been shown to affect other anabolic processes through up-regulation of mTORC1 and 564 
MYC activity, and it is therefore plausible that changes of CIP2A level may affect local levels 565 
of amino acids and other metabolites. The present finding of AMPK activity and autophagy in 566 
relation to CIP2A may therefore be important for other effects including mitophagy, and also 567 
in other cancer types. 568 
     CIP2A may confer resistance to tyrosine kinase inhibitor therapy in CML, as previously 569 
published [5]. The present data extend those clinical findings by demonstrating a novel role 570 
for CIP2A on cellular metabolic processes, involving AMPK. This may drive several 571 
pathways conferring treatment resistance in CML, including increased OXPHOS [51], 572 
increased mTORC1 activity [52] and autophagy as recently reviewed [53]. In malignant cells 573 
with adequate nutrient conditions, CIP2A+ cells may outcompete normal cells for nutrients, 574 
as AMPK-driven catabolic processes are likely increased, involving glucose uptake and 575 
enhanced ATP production by OXPHOS, despite lower glycolytic activity. Conversely, in a 576 
low nutrient environment of rapidly growing or necrotic epithelial tumours or in the hypoxia of 577 
the marrow niche, cells with high CIP2A levels may have AMPK activity suppressed to lower 578 
levels than if well supplied with nutrients, which may relieve AMPK inhibition of mTOR 579 
signalling, driving anabolic processes such as protein synthesis and cell growth, whose 580 
dysregulation is known to contribute to malignancy and other cellular dysfunction [54]. 581 
Similar observations have been shown in human breast cancer cells, where elevated CIP2A 582 
led to enhanced mTORC1 activity [55]. In a high nutrient environment with high CIP2A 583 
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levels, both catabolic and anabolic processes can therefore occur at the same time, directed 584 
by both AMPK and mTORC1, as recently reviewed in CML [53]. 585 
     In summary, a novel action of CIP2A on energy metabolism is described. Further work is 586 
needed to investigate how CIP2A affects AMPK activity and how this is modified by the 587 
prevailing nutrient availability, since targeting this interaction may be a potential Achilles heel 588 
of the malignant cell. 589 
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 851 
Figure 1. Validation of CIP2A status in lentiviral K562 cell lines and fractionation. 852 
     Panel A: Western blot analysis and resultant densitometry plots demonstrating the 853 
relative level of CIP2A and functionally associated proteins MYC and PP2A between 854 
unmodified and CIP2A modified cell lines. Levels are expressed as mean +/- standard error 855 
of at least 3 replicates. * denotes p < 0.05 using unpaired Student’s T –test). Panel B: 856 
Cytoplasmic and nuclear fractionation of unmodified and CIP2A modified cell lysates 857 
showing cellular location of CIP2A, MYC and P-Tyr-307-PP2A and PP2A’s catalytic subunit.  858 
Panel C: Distribution of cell population in flow cytometry side and forward scatter, with 859 
relative sizes demonstrated through forward scatter overlay in high (24h after feeding) and 860 
low (72h after feeding) nutrient conditions. Panel D: Effect of starvation on viability in CIP2A 861 
modified cells after 72h media starvation, determined through annexin V and propidium 862 
iodide (PI) uptake in flow cytometry.  863 
 864 
Figure 2. The effect of CIP2A level on seahorse energy metabolic stress assays of 865 
glycolysis (panels A-E) and OXPHOS (panels F-K). 866 
   Panel A: Annotated experimental data for the CIP2A manipulated and unmodified cell 867 
lines, normalised to the non-glycolytic acidification (mean of 3 experiments with standard 868 
errors). Compounds were injected at times indicated to manipulate glycolysis and measure 869 
different metabolic components through changes in the levels of extracellular acidification 870 
rate (ECAR). Panel B, basal glycolysis (** p<0.0001), Panel C, maximum glycolytic capacity 871 
and Panel D, spare capacity (* p=0.0435, ** p<0.002) express these data as means +/- 872 
standard error from their 3 contributory time points (each with n=3). Statistical analysis is by 873 
unpaired Student’s T-test, with Welch correction). 874 
     Panel E: Experimental profiles for OXPHOS, annotated with compounds injected and 875 
components of OXPHOS that were measured through assessing levels of the oxygen 876 
consumption rate (OCR). Panels F-I depict the data of panel E analogous to that of panels A 877 
and B-D; (mean of 3 experiments with standard error). Panel F, basal aerobic respiration (* 878 
p=0.0353, ** p<0.0001), Panel G, ATP production (** <0.0001), Panel H, maximum 879 
respiration (** p<0.005) and Panel I, spare mitochondrial capacity (** p<0.007). Time points 880 
used as indicated by * in panel A and E respectively 881 
 882 
Figure 3. CIP2A driven proteomic changes assessed by quantitative mass 883 
spectrometry and ITRAQ. 884 
    Panel A:  Heat map showing 229 proteins whose expression in either (or both) CIP2A+ or 885 
CIP2A- differed significantly (FE p < 0.05; see text) from unmodified cells. Panel B: Heat 886 
map of DAVID analysis on upregulated proteins and enrichment in energy metabolic 887 
pathways as identified by KEGG (FE p <0.05). Panel C: DAVID analysis on proteins down 888 
regulated with elevated CIP2A and KEGG pathway enrichment in energy metabolic 889 
processes (FE p<0.05).  890 
 891 
Figure 4. CIP2A associating proteins.  Panel A; Venn diagram showing the total proteins 892 
derived from the N- and C-terminus targeted immunoprecipitation experiments (IP#1 and 893 
IP#2) and CIP2A-venus extraction. Panel B: These 52 common proteins were input into the 894 
functional protein interaction network STRING software. Proteins are represented by circular 895 
18 
 
nodes and interactions by a straight line edge, with line thickness representing the 896 
confidence of the interaction based on experimental, co-expression and text mining data 897 
incorporated within STRING search parameters (17). Interaction confidence limit was set to 898 
medium (0.4 out of 1.0). Proteins enriched using DAVID are shown as coloured nodes 899 
alongside the identified KEGG pathway and enrichment p value. 900 
 901 
 902 
Figure 5. CIP2A nutrient dependent regulation of AMPK.  Panel A: Western blot showing 903 
levels of CIP2A, AMPK, P-Thr-172 AMPK , P-Ser-62-Myc, the AMPK substrate GLUT4 and 904 
actin loading controls in low (fed 72 hours earlier) and high (fed 24 hours earlier) nutrient 905 
conditions, with relative quantitation by densitometry, normalised to the low unmodified 906 
condition (n=3, unpaired Student T-test)  * and ** indicate p<0.05 and <0.01 respectively.  907 
Panel B:  Western blots of ULK-1 phosphorylation at Ser555 (P-Ser-555-ULK-1) and LC3I 908 
and II, markers of autophagy, in low (72h) and high (24h) nutrient states, with relative 909 
quantitation of the LC3II/LC3I ratio. * and ** are as for panel A. Panel C: PP2A inhibition by 910 
the phosphatase inhibitor okadaic acid at 5 and 10 nMolar in CIP2A- cells, showing an 911 
increase in AMPK activity (P-Thr-172-AMPK).  912 
 913 
Figure 6. Manipulation of AMPK activity can regulate OXPHOS activity. 914 
Panel A: OXPHOS assay in CIP2A- cells in high nutrient conditions (i.e. low AMPK activity), 915 
with AICAR added as shown, and effect on P-Ser-172-AMPK level as shown by western 916 
blot. Panel B: Column plots for the experiment in panel A: * = p <0.05, ** = p<0.01. Panel C: 917 
OXPHOS assay in CIP2A+ cells in high nutrient conditions (i.e. high AMPK activity) showing 918 
the effect of Compound C (CC) on basal and maximal OXPHOS capacity and effect on P-919 
Ser-172-AMPK level. Panel D: column plots of the experiment in panel D.  * = p<0.05 and ** 920 
= p<0.01. 921 
 922 
 923 






Supplementary Table S1.  Supplementary to Figure 3, list of the 229 proteins that 
significantly differ between CIP2A+ and CIP2A- cell lines with corresponding Log2 values. 
Expression calculated on CIP2A+ vs CIP2A- cells (p < 0.05, ANOVA, FC = Fold Change). 
See supplementary material file. 
 
Supplementary Table S1. 
#  Accession# Gene ID Protein Name Ratio Log2
FC 
pValue 
1  Q16698 DECR1 2,4-dienoyl-CoA reductase 1, 
mitochondrial 
0.8 -1.3 0.00750 
2  Q6NVY1 HIBCH 3-hydroxyisobutyryl-CoA 
hydrolase 
0.6 -1.6 0.00327 
3  P31939 ATIC 5-aminoimidazole-4-carboxamide 
ribonucleotide 
formyltransferase/IMP 
cyclohydrolase 
0.7 -1.4 0.00805 
4  Q5TFE4 NT5DC1 5'-nucleotidase domain containing 
1 
0.7 -1.4 0.01309 
5  O96019 ACTL6A actin like 6A 0.7 -1.4 0.01869 
6  O43707 ACTN4 actinin alpha 4 0.6 -1.6 0.02803 
7  O00154 ACOT7 acyl-CoA thioesterase 7 1.2 1.2 0.00964 
8  P55263 ADK adenosine kinase 0.6 -1.8 0.00776 
9  P18085 ARF4 ADP ribosylation factor 4 0.7 -1.5 0.01545 
10  P55196 AFDN afadin, adherens junction formation 
factor 
1.8 1.8 0.00002 
11  Q5JTZ9 AARS2 alanyl-tRNA synthetase 2, 
mitochondrial 
0.7 -1.3 0.02558 
12  P30038 ALDH4A1 aldehyde dehydrogenase 4 family 
member A1 
0.6 -1.6 0.02827 
13  Q13155 AIMP2 aminoacyl tRNA synthetase 
complex interacting 
multifunctional protein 2 
0.7 -1.4 0.00656 
14  Q8IWZ3 ANKHD1 ankyrin repeat and KH domain 
containing 1 
1.4 1.4 0.02536 
15  P07355 ANXA2 annexin A2 0.6 -1.6 0.00547 
16  P27695 APEX1 apurinic/apyrimidinic 
endodeoxyribonuclease 1 
1.5 1.5 0.02598 
17  O43681 bacterial arsA arsenite transporter, ATP-
binding, homolog 1  
2.0 2.0 0.00049 
18  O43776 NARS asparaginyl-tRNA synthetase 1.6 1.6 0.00464 
19  P06576 ATP5B ATP synthase, H+ transporting, 
mitochondrial F1 complex, beta 
polypeptide 
1.6 1.6 0.01267 
20  Q5T9A4 ATAD3B ATPase family, AAA domain 
containing 3B 
1.4 1.4 0.02727 
21  Q96GS4 BORCS6 BLOC-1 related complex subunit 6 1.4 1.4 0.01662 
22  Q13895 BYSL bystin like 1.6 1.6 0.00534 
23  P0DP25 CALM1 calmodulin 1 0.6 -1.6 0.03004 
24  P47756 CAPZB capping actin protein of muscle Z-
line beta subunit 
0.7 -1.5 0.01821 
25  P27708 CAD carbamoyl-phosphate synthetase 2, 
aspartate transcarbamylase, and 
dihydroorotase 
0.7 -1.5 0.02329 
26  P42574 CASP3 caspase 3 0.8 -1.3 0.02782 
27  P35221 CTNNA1 catenin alpha 1 1.6 1.6 0.00187 
28  Q8IX12 CCAR1 cell division cycle and apoptosis 
regulator 1 
0.6 -1.6 0.00331 
29  P49454 CENPF centromere protein F 0.6 -1.6 0.00688 
30  P78371 CCT2 chaperonin containing TCP1 0.7 -1.4 0.00812 
subunit 2 
31  P50991 CCT4 chaperonin containing TCP1 
subunit 4 
0.7 -1.4 0.02356 
32  P48643 CCT5 chaperonin containing TCP1 
subunit 5 
0.6 -1.6 0.02345 
33  P40227 CCT6A chaperonin containing TCP1 
subunit 6A 
0.6 -1.6 0.00229 
34  Q99832 CCT7 chaperonin containing TCP1 
subunit 7 
0.6 -1.6 0.00301 
35  Q9H444 CHMP4B charged multivesicular body 
protein 4B 
1.5 1.5 0.00727 
36  Q86X55 CARM1 coactivator associated arginine 
methyltransferase 1 
1.4 1.4 0.01308 
37  Q9UBF2 COPG2 coatomer protein complex subunit 
gamma 2 
0.6 -1.6 0.01454 
38  O60826 CCDC22 coiled-coil domain containing 22 1.2 1.2 0.01807 
39  Q13951 CBFB core-binding factor beta subunit 0.8 -1.3 0.00336 
40  Q9BR76 CORO1B coronin 1B 0.7 -1.4 0.01143 
41  Q9NRF8 CTPS2 CTP synthase 2 0.7 -1.3 0.02115 
42  Q9P0U4 CXXC1 CXXC finger protein 1 1.2 1.2 0.02611 
43  P24941 CDK2 cyclin dependent kinase 2 0.6 -1.7 0.00699 
44  P10606 COX5B cytochrome c oxidase subunit 5B 1.6 1.6 0.01818 
45  O76071 CIAO1 cytosolic iron-sulfur assembly 
component 1 
0.8 -1.2 0.02340 
46  Q16531 DDB1 damage specific DNA binding 
protein 1 
0.7 -1.4 0.01468 
47  Q96GQ7 DDX27 DEAD-box helicase 27 1.2 1.2 0.01984 
48  P26196 DDX6 DEAD-box helicase 6 0.7 -1.4 0.00307 
49  P35659 DEK DEK proto-oncogene 0.7 -1.4 0.00927 
50  Q7L2E3 DHX30 DExH-box helicase 30 1.4 1.4 0.02009 
51  Q68CQ4 zebrafish digestive organ expansion factor 
homolog  
1.3 1.3 0.01282 
52  P00374 DHFR dihydrofolate reductase 1.3 1.3 0.01682 
53  O43314 PPIP5K2 diphosphoinositol 
pentakisphosphate kinase 2 
2.0 2.0 0.00012 
54  Q8IYB7 DIS3L2 DIS3 like 3'-5' exoribonuclease 2 0.7 -1.5 0.02074 
55  P25685 DNAJB1 DnaJ heat shock protein family 
(Hsp40) member B1 
1.8 1.8 0.00038 
56  Q9NVH1 DNAJC11 DnaJ heat shock protein family 
(Hsp40) member C11 
1.5 1.5 0.00969 
57  Q99543 DNAJC2 DnaJ heat shock protein family 
(Hsp40) member C2 
0.7 -1.4 0.00117 
58  Q9UNI6 DUSP12 dual specificity phosphatase 12 0.7 -1.4 0.01910 
59  Q13409 DYNC1I2 dynein cytoplasmic 1 intermediate 
chain 2 
0.7 -1.5 0.00172 
60  P63167 DYNLL1 dynein light chain LC8-type 1 0.7 -1.4 0.00194 
61  Q96HE7 ERO1A endoplasmic reticulum 
oxidoreductase 1 alpha 
0.6 -1.6 0.01905 
62  O43491 EPB41L2 erythrocyte membrane protein band 
4.1 like 2 
2.1 2.1 0.01171 
63  Q05639 EEF1A2 eukaryotic translation elongation 
factor 1 alpha 2 
0.5 -1.9 0.02423 
64  P05198 EIF2S1 eukaryotic translation initiation 
factor 2 subunit alpha 
1.5 1.5 0.00048 
65  P20042 EIF2S2 eukaryotic translation initiation 
factor 2 subunit beta 
1.6 1.6 0.00033 
66  P41091 EIF2S3 eukaryotic translation initiation 
factor 2 subunit gamma 
1.8 1.8 0.00148 
67  Q15056 EIF4H eukaryotic translation initiation 
factor 4H 
1.7 1.7 0.00728 
68  Q8TAG9 EXOC6 exocyst complex component 6 0.7 -1.4 0.00945 
69  Q06265 EXOSC9 exosome component 9 1.5 1.5 0.01084 
70  Q96TA1 FAM129B family with sequence similarity 
129 member B 
0.6 -1.6 0.00030 
71  Q9Y3D0 FAM96B family with sequence similarity 96 
member B 
0.7 -1.4 0.00703 
72  Q96AE4 FUBP1 far upstream element binding 
protein 1 
0.6 -1.6 0.01686 
73  P14324 FDPS farnesyl diphosphate synthase 1.5 1.5 0.01210 
74  Q14254 FLOT2 flotillin 2 1.9 1.9 0.02498 
75  Q8IY81 FTSJ3 FtsJ homolog 3 1.5 1.5 0.00212 
76  Q9BVP2 GNL3 G protein nucleolar 3 1.8 1.8 0.00522 
77  Q8TAE8 GADD45GIP1 GADD45G interacting protein 1 0.8 -1.2 0.02997 
78  Q9NY12 GAR1 GAR1 ribonucleoprotein 1.5 1.5 0.01006 
79  P31150 GDI1 GDP dissociation inhibitor 1 0.7 -1.5 0.01866 
80  O60547 GMDS GDP-mannose 4,6-dehydratase 0.7 -1.5 0.02654 
81  Q96IJ6 GMPPA GDP-mannose pyrophosphorylase 
A 
0.7 -1.5 0.02541 
82  O14908 GIPC1 GIPC PDZ domain containing 
family member 1 
1.8 1.8 0.00449 
83  Q06210 GFPT1 glutamine--fructose-6-phosphate 
transaminase 1 
0.7 -1.5 0.00580 
84  Q9UJY5 GGA1 golgi associated, gamma adaptin 
ear containing, ARF binding 
protein 1 
1.8 1.8 0.01535 
85  Q9H8Y8 GORASP2 golgi reassembly stacking protein 2 1.3 1.3 0.02927 
86  Q9Y450 HBS1L HBS1 like translational GTPase 0.8 -1.3 0.02742 
87  P14625 HSP90B1 heat shock protein 90 beta family 
member 1 
0.5 -1.9 0.00990 
88  P02100 HBE1 hemoglobin subunit epsilon 1 6.0 6.0 0.00130 
89  P05114 HMGN1 high mobility group nucleosome 
binding domain 1 
2.4 2.4 0.02945 
90  Q71DI3 HIST2H3C histone cluster 2 H3 family 
member c 
2.0 2.0 0.02183 
91  Q9UBN7 HDAC6 histone deacetylase 6 0.6 -1.5 0.02763 
92  P08397 HMBS hydroxymethylbilane synthase 3.4 3.4 0.02439 
93  Q8NBQ5 HSD17B11 hydroxysteroid 17-beta 
dehydrogenase 11 
0.6 -1.7 0.02828 
94  P12268 IMPDH2 inosine monophosphate 
dehydrogenase 2 
0.6 -1.7 0.02500 
95  Q9H1B7 IRF2BPL interferon regulatory factor 2 
binding protein like 
2.0 2.0 0.03020 
96  Q9ULR0 ISY1 ISY1 splicing factor homolog 1.5 1.5 0.00262 
97  O00629 KPNA4 karyopherin subunit alpha 4 1.5 1.5 0.00094 
98  Q92945 KHSRP KH-type splicing regulatory 
protein 
1.7 1.7 0.00005 
99  Q8TCG1 KIAA1524 KIAA1524 31.6 31.6 1.08e-11 
100  Q96EK9 KTI12 KTI12 chromatin associated 
homolog 
1.6 1.6 0.02983 
101  Q16773 KYAT1 kynurenine aminotransferase 1 0.7 -1.4 0.00118 
102  P20700 LMNB1 lamin B1 1.9 1.9 0.00421 
103  P49257 LMAN1 lectin, mannose binding 1 1.3 1.3 0.00521 
104  P09960 LTA4H leukotriene A4 hydrolase 0.7 -1.5 0.01257 
105  P48163 ME1 malic enzyme 1 1.3 1.3 0.02611 
106  P34949 MPI mannose phosphate isomerase 0.6 -1.8 0.01273 
107  O95983 MBD3 methyl-CpG binding domain 
protein 3 
1.4 1.4 0.01772 
108  Q96E11 MRRF mitochondrial ribosome recycling 
factor 
0.8 -1.3 0.01737 
109  P27361 MAPK3 mitogen-activated protein kinase 3 0.8 -1.3 0.00357 
110  P36507 MAP2K2 mitogen-activated protein kinase 
kinase 2 
0.7 -1.4 0.01051 
111  Q8NI22 MCFD2 multiple coagulation factor 
deficiency 2 
0.6 -1.6 0.02722 
112  Q96EY5 MVB12A multivesicular body subunit 12A 0.6 -1.7 0.00311 
113  P43246 MSH2 mutS homolog 2 0.7 -1.4 0.02085 
114  P35579 MYH9 myosin heavy chain 9 1.9 1.9 0.00076 
115  P16083 NQO2 NAD(P)H quinone dehydrogenase 
2 
0.6 -1.7 0.00366 
116  O95182 NDUFA7 NADH:ubiquinone oxidoreductase 
subunit A7 
1.5 1.5 0.00673 
117  Q16795 NDUFA9 NADH:ubiquinone oxidoreductase 
subunit A9 
1.8 1.8 0.01332 
118  Q9H3P2 NELFA negative elongation factor complex 
member A 
1.3 1.3 0.00477 
119  Q8NEJ9 NGDN neuroguidin 1.6 1.6 0.01186 
120  Q9ULX3 NOB1 NIN1/PSMD8 binding protein 1 
homolog 
1.4 1.4 0.00801 
121  P78316 NOP14 NOP14 nuc+D2:D251leolar 
protein 
1.6 1.6 0.00387 
122  Q9Y3C1 NOP16 NOP16 nucleolar protein 1.4 1.4 0.02037 
123  Q08J23 NSUN2 NOP2/Sun RNA methyltransferase 
family member 2 
1.6 1.6 0.02112 
124  Q9UKX7 NUP50 nucleoporin 50 2.8 2.8 8.09e-9 
125  P53384 NUBP1 nucleotide binding protein 1 0.5 -1.9 0.00099 
126  O60313 OPA1 OPA1, mitochondrial dynamin like 
GTPase 
0.8 -1.3 0.00959 
127  Q96FW1 OTUB1 OTU deubiquitinase, ubiquitin 
aldehyde binding 1 
0.6 -1.7 0.00922 
128  O95747 OXSR1 oxidative stress responsive 1 0.6 -1.6 0.00796 
129  Q10713 PMPCA peptidase, mitochondrial 
processing alpha subunit 
0.7 -1.4 0.01229 
130  Q6GMV3 PTRHD1 peptidyl-tRNA hydrolase domain 
containing 1 
0.6 -1.7 0.00742 
131  O60664 PLIN3 perilipin 3 0.5 -2.2 0.00417 
132  P30048 PRDX3 peroxiredoxin 3 0.6 -1.7 0.01195 
133  P49585 PCYT1A phosphate cytidylyltransferase 1, 
choline, alpha 
1.5 1.5 0.00030 
134  Q01813 PFKP phosphofructokinase, platelet 0.3 -2.9 0.00034 
135  P52209 PGD phosphogluconate dehydrogenase 0.7 -1.3 0.02385 
136  P11908 PRPS2 phosphoribosyl pyrophosphate 
synthetase 2 
0.8 -1.3 0.01686 
137  P11216 PYGB phosphorylase, glycogen; brain 0.6 -1.5 0.02994 
138  P78330 PSPH phosphoserine phosphatase 0.7 -1.5 0.02233 
139  P53801 PTTG1IP pituitary tumor-transforming 1 
interacting protein 
1.8 1.8 0.00011 
140  Q9Y446 PKP3 plakophilin 3 1.5 1.5 0.00579 
141  O43242 PSMD3 proteasome 26S subunit, non-
ATPase 3 
1.7 1.7 0.02593 
142  Q15008 PSMD6 proteasome 26S subunit, non-
ATPase 6 
1.7 1.7 0.00173 
143  Q9UL46 PSME2 proteasome activator subunit 2 0.5 -2.0 0.01916 
144  P20618 PSMB1 proteasome subunit beta 1 0.6 -1.6 0.00108 
145  O14744 PRMT5 protein arginine methyltransferase 
5 
0.7 -1.5 0.00374 
146  P30101 PDIA3 protein disulfide isomerase family 
A member 3 
0.4 -2.5 0.00109 
147  Q15084 PDIA6 protein disulfide isomerase family 
A member 6 
0.5 -2.0 0.02041 
148  Q13131 PRKAA1 protein kinase AMP-activated 0.7 -1.4 0.00034 
catalytic subunit alpha 1 
149  P54619 PRKAG1 protein kinase AMP-activated non-
catalytic subunit gamma 1 
0.8 -1.3 0.01902 
150  P62140 PPP1CB protein phosphatase 1 catalytic 
subunit beta 
0.7 -1.4 0.02243 
151  O14974 PPP1R12A protein phosphatase 1 regulatory 
subunit 12A 
0.6 -1.6 0.00178 
152  Q15172 PPP2R5A protein phosphatase 2 regulatory 
subunit B'alpha 
0.6 -1.5 0.00791 
153  P30154 PPP2R1B protein phosphatase 2 scaffold 
subunit Abeta 
0.5 -1.9 0.02214 
154  Q9Y570 PPME1 protein phosphatase methylesterase 
1 
1.3 1.3 0.03073 
155  Q86TP1 PRUNE1 prune exopolyphosphatase 0.6 -1.6 0.02140 
156  Q08623 PUDP pseudouridine 5'-phosphatase 0.6 -1.7 0.01141 
157  Q9NVS9 PNPO pyridoxamine 5'-phosphate oxidase 0.8 -1.2 0.02008 
158  P30613 PKLR pyruvate kinase, liver and RBC 2.6 2.6 0.00054 
159  P14618 PKM pyruvate kinase, muscle 1.7 1.7 0.01963 
160  Q9UL25 RAB21 RAB21, member RAS oncogene 
family 
0.7 -1.4 0.00572 
161  P51149 RAB7A RAB7A, member RAS oncogene 
family 
1.6 1.6 0.00014 
162  Q15293 RCN1 reticulocalbin 1 0.7 -1.5 0.01503 
163  P13489 RNH1 ribonuclease/angiogenin inhibitor 1 0.6 -1.6 0.02427 
164  P23921 RRM1 ribonucleotide reductase catalytic 
subunit M1 
0.6 -1.6 0.00854 
165  P47914 RPL29 ribosomal protein L29 1.4 1.4 0.01476 
166  P62249 RPS16 ribosomal protein S16 1.6 1.6 0.03079 
167  Q5JTH9 RRP12 ribosomal RNA processing 12 
homolog 
1.7 1.7 0.00767 
168  Q9P2E9 RRBP1 ribosome binding protein 1 0.6 -1.7 0.00081 
169  Q9BTD8 RBM42 RNA binding motif protein 42 1.3 1.3 0.00699 
170  Q9Y3B8 REXO2 RNA exonuclease 2 2.1 2.1 0.00276 
171  O15160 POLR1C RNA polymerase I subunit C 1.3 1.3 0.01159 
172  O14802 POLR3A RNA polymerase III subunit A 1.5 1.5 0.02573 
173  Q9BUI4 POLR3C RNA polymerase III subunit C 1.4 1.4 0.01835 
174  Q6R327 RICTOR RPTOR independent companion of 
MTOR complex 2 
0.9 -1.1 0.00649 
175  O94901 SUN1 Sad1 and UNC84 domain 
containing 1 
1.5 1.5 0.00293 
176  Q9NSI8 SAMSN1 SAM domain, SH3 domain and 
nuclear localization signals 1 
1.9 1.9 0.02554 
177  Q15436 SEC23A Sec23 homolog A, coat complex II 
component 
0.7 -1.4 0.02542 
178  P53992 SEC24C SEC24 homolog C, COPII coat 
complex component 
0.6 -1.6 0.02093 
179  Q16181 SEPT7 septin 7 0.8 -1.3 0.01129 
180  Q96GA7 SDSL serine dehydratase like 0.7 -1.5 0.01394 
181  Q99961 SH3GL1 SH3 domain containing GRB2 like 
1, endophilin A2 
1.3 1.3 0.03055 
182  Q9BWW4 SSBP3 single stranded DNA binding 
protein 3 
1.9 1.9 0.01116 
183  O43765 SGTA small glutamine rich 
tetratricopeptide repeat containing 
alpha 
0.7 -1.4 0.01338 
184  P08579 SNRPB2 small nuclear ribonucleoprotein 
polypeptide B2 
0.8 -1.2 0.00531 
185  P62308 SNRPG small nuclear ribonucleoprotein 
polypeptide G 
1.4 1.4 0.00383 
186  P14678 SNRPB small nuclear ribonucleoprotein 1.3 1.3 0.02297 
polypeptides B and B1 
187  P11166 SLC2A1 solute carrier family 2 member 1 2.0 2.0 0.00073 
188  P11169 SLC2A3 solute carrier family 2 member 3 2.4 2.4 0.00087 
189  Q9Y6M7 SLC4A7 solute carrier family 4 member 7 0.8 -1.3 0.02290 
190  Q96SB4 SRPK1 SRSF protein kinase 1 1.4 1.4 0.01642 
191  Q9BRK5 SDF4 stromal cell derived factor 4 0.7 -1.4 0.00207 
192  Q13586 STIM1 stromal interaction molecule 1 1.2 1.2 0.01705 
193  P04179 SOD2 superoxide dismutase 2, 
mitochondrial 
0.6 -1.6 0.00688 
194  Q8IYB8 SUPV3L1 Suv3 like RNA helicase 1.4 1.4 0.00859 
195  Q96A49 SYAP1 synapse associated protein 1 0.9 -1.1 0.02492 
196  Q9Y490 TLN1 talin 1 0.5 -1.8 0.00969 
197  P17987 TCP1 t-complex 1 0.6 -1.6 0.02344 
198  O43156 TTI1 TELO2 interacting protein 1 1.4 1.4 0.02114 
199  Q6NXR4 TTI2 TELO2 interacting protein 2 1.5 1.5 0.01511 
200  Q9Y4R8 TELO2 telomere maintenance 2 1.5 1.5 0.00220 
201  O95881 TXNDC12 thioredoxin domain containing 12 0.5 -1.9 0.02849 
202  P04818 TYMS thymidylate synthetase 1.5 1.5 0.02532 
203  Q9H0E2 TOLLIP toll interacting protein 1.3 1.3 0.00458 
204  Q99598 TSNAX translin associated factor X 0.7 -1.4 0.01486 
205  Q9BTV4 TMEM43 transmembrane protein 43 2.1 2.1 0.01475 
206  O14787 TNPO2 transportin 2 2.6 2.6 0.00002 
207  Q9UPN9 TRIM33 tripartite motif containing 33 1.1 1.1 0.01969 
208  Q6IBS0 TWF2 twinfilin actin binding protein 2 0.8 -1.3 0.02241 
209  P26368 U2AF2 U2 small nuclear RNA auxiliary 
factor 2 
1.4 1.4 0.02666 
210  Q9NRR5 UBQLN4 ubiquilin 4 0.6 -1.8 0.00154 
211  Q5T6F2 UBAP2 ubiquitin associated protein 2 1.3 1.3 0.02035 
212  Q14157 UBAP2L ubiquitin associated protein 2 like 0.6 -1.6 0.00643 
213  P22314 UBA1 ubiquitin like modifier activating 
enzyme 1 
0.5 -2.0 0.00240 
214  O94966 USP19 ubiquitin specific peptidase 19 0.6 -1.6 0.00673 
215  Q86UV5 USP48 ubiquitin specific peptidase 48 0.6 -1.8 0.00613 
216  P45974 USP5 ubiquitin specific peptidase 5 1.4 1.4 0.01126 
217  Q9NYU2 UGGT1 UDP-glucose glycoprotein 
glucosyltransferase 1 
0.6 -1.6 0.00753 
218  Q9HAU5 yeast UPF2 regulator of nonsense 
transcripts homolog  
1.4 1.4 0.02109 
219  O60287 URB1 URB1 ribosome biogenesis 1 
homolog 
1.4 1.4 0.02046 
220  O75691 UTP20 UTP20, small subunit processome 
component 
1.4 1.4 0.02863 
221  Q9Y277 VDAC3 voltage dependent anion channel 3 1.3 1.3 0.01835 
222  Q9P253 VPS18 VPS18, CORVET/HOPS core 
subunit 
1.3 1.3 0.02611 
223  O15213 WDR46 WD repeat domain 46 1.2 1.2 0.02588 
224  Q9Y2W2 WBP11 WW domain binding protein 11 1.3 1.3 0.01160 
225  Q9HCS7 XAB2 XPA binding protein 2 1.5 1.5 0.01598 
226  Q86WB0 ZC3HC1 zinc finger C3HC-type containing 
1 
0.8 -1.3 0.00882 
227  Q9Y4E5 ZNF451 zinc finger protein 451 0.6 -1.7 0.02582 
228  Q14966 ZNF638 zinc finger protein 638 0.7 -1.5 0.02758 
229  O75312 ZPR1 ZPR1 zinc finger 0.7 -1.5 0.00236 
 
